Premium
Molecular and immunohistochemical analysis of the bcl ‐1/ cyclin D1 gene in laryngeal squamous cell carcinomas
Author(s) -
Fracchiolla Nicola S.,
Pruneri Giancarlo,
Pignataro Lorenzo,
Carboni Nadia,
Capaccio Pasquale,
Boletini Alketa,
Buffa Roberto,
Neri Antonino
Publication year - 1997
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19970315)79:6<1114::aid-cncr9>3.0.co;2-f
Subject(s) - cyclin d1 , lymph node , cancer research , medicine , cyclin d , pathogenesis , pathology , immunohistochemistry , locus (genetics) , cyclin b , cyclin , dysplasia , cancer , cell cycle , biology , gene , genetics
BACKGROUND The molecular pathogenesis of laryngeal squamous cell carcinomas (LSCCs) is still only partially understood, although genetic alterations affecting various protooncogenes or tumor suppressor genes have often been detected. METHODS To improve their understanding of the role of cyclin D1 in the pathogenesis of LSCCs, the authors investigated the expression of cyclin D1 protein and the amplification status of the bcl ‐1/ cyclin D1 locus in a panel of 58 pathologic samples. RESULTS Expression of cyclin D1 protein was detected in 23 of the 58 patients(≈39%), 14 of whom had lymph node metastases (≈61%); of the remaining 35 patients without any detectable cyclin D1 expression, 7 had lymph node metastases (20%). Expression of cyclin D1 was detectable in 5% of the specimens of normal mucosa, 13% of those with mild‐to‐moderate dysplasia, and 25% of those with severe dysplasia. Amplification of the bcl ‐1/ cyclin D1 locus was detected in 12 of the 49 LSCCs investigated (≈24%), 7 of which had lymph node metastases (≈58%); of the remaining 37 LSCCs with an apparently normal copy number of the cyclin D1 locus, 12 had lymph node metastases (≈32%). The authors found almost complete concordance between locus amplification and protein expression. Statistical analysis showed a correlation between cyclin D1 expression and both the presence of lymph node metastases ( P < 0.01) and advanced clinical stage ( P < 0.02). CONCLUSIONS The authors' observations suggest that the deregulation of cyclin D1 expression may be involved in the pathogenesis of more aggressive LSCCs. Cancer 1997; 79:1114‐21. © 1997 American Cancer Society.